ClinicalTrials.gov
ClinicalTrials.gov Menu

Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02839681
Recruitment Status : Completed
First Posted : July 21, 2016
Last Update Posted : June 14, 2018
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

Brief Summary:

Background:

Anetumab ravtansine is a new drug. It kills cancer cells that carry mesothelin. That is a protein on the surface of tumor cells in many types of tumors, including most lung cancers. Researchers want to find a safe dose for the study drug for lung cancer. They want to see if it can shrink tumors in mesothelin-positive lung cancer.

Objectives:

To test the safety and effectiveness of anetumab ravtansine for lung cancer.

Eligibility:

Adults 18 years and older who have lung cancer that has gotten worse on other therapy

Design:

Participants will be screened with:

Medical history

Physical exam

Tumor tissue sample. This can be from a previous procedure.

Blood and urine tests

Heart tests

Scans. For one scan, a small amount of radioactive substance is injected into the blood.

Eye exam

The study will have 21-day cycles.

On day 1 of each cycle, participants will get the study drug through a tube inserted in a vein.

Participants will repeat a heart test in cycles 1 and 2.

They will have blood tests weekly in cycle 1, twice in all other cycles.

They will have scans every 6 weeks for the first 6 months, every 9 weeks until the end of year 2, then every 12 weeks.

Participants will have samples of tumor tissue taken twice.

About 30 days after stopping the study drug, participants will have a follow-up visit. This will include medical history, physical exam, blood and pregnancy tests, and heart and eye tests.

Some will be called a few times a year to discuss their health and treatment.


Condition or disease Intervention/treatment Phase
Lung Neoplasms Drug: Anetumab Ravtansine Device: Blood test Phase 2

Expanded Access : National Cancer Institute (NCI) has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.  

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial With Safety Run-in of the Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
Study Start Date : July 19, 2016
Actual Primary Completion Date : June 12, 2018
Actual Study Completion Date : June 12, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1/Safety Run-in Arm
Subjects will be dosed with the higher of the 2 possible anetumab ravtansine doses (dose level 1) evaluated on the study
Drug: Anetumab Ravtansine
Administered IV every 3 weeks

Device: Blood test
Research blood test for eligibility

Experimental: 2/Phase 2 Arm
Subjects will be dosed with anetumab ravtansineat the recommended phase 2 dose (dose level1 if no more than 1 DLT occurred in the safety runin arm, or at dose level -1 otherwise)
Drug: Anetumab Ravtansine
Administered IV every 3 weeks

Device: Blood test
Research blood test for eligibility




Primary Outcome Measures :
  1. Recommended Phase 2 Dose [ Time Frame: 21 days after initiation of study therapy ]
    The highest dose tested at which no more than 1 dose limiting toxicity occurs

  2. Objective Response Rate [ Time Frame: Every 6 weeks (first 6 months), Every 9 weeks (until end of year 2), Every 12 weeks thereafter ]
    proportion of subjects who experience partial or complete response


Secondary Outcome Measures :
  1. Progression Free Survival [ Time Frame: At Disease Progression ]
    Length of time from start of treatment to time of progression or death, whichever occurs first

  2. Duration of Response [ Time Frame: At Disease Progression ]
    from the time measurement criteria are met for CR or PR Length of time criteria are met for partial response or complete response(whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented

  3. Overall Survival [ Time Frame: At Death ]
    Length of time from start of treatment to death from any cause



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • INCLUISION CRITERIA:

Subjects must have histologically or cytologically confirmed previously treated unresectable mesothelin expressing advanced lung adenocarcinoma (stage IIIB or IV) as confirmed by the Laboratory of Pathology, NCI

Subjects must have positive mesothelin expression in the archival tumor tissue, defined as the mesothelin membrane intensity score of 2+ or 3+ (on the 0-3 scale) expressed on the membrane of greater than or equal to 10% of tumor cells.

Subjects must provide sample of archival tumor tissue (tissue block preferred, at least 5 formalin-fixated, paraffin-embedded [FFPE] slides acceptable) collected any time before the general screening. A fresh biopsy will be collected if archival sample is

unavailable or insufficient.

Subjects must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for nonnodal lesions and short axis for nodal lesions) as >20 mm with conventional techniques or as >10 mm with spiral CT scan. See Section 6.3 for the evaluation of measurable disease.

Subjects with resected primary tumors who have documented metastases are eligible.

Subjects should have received at least one prior platinum based chemotherapy and an immune checkpoint targeted agent. Subjects with epidermal growth factor receptor [EGFR]-mutated and anaplastic lymphoma kinase [ALK]-translocated NSCLC

should have received FDA-approved targeted therapies as appropriate.

Age >18 years. Because no dosing or adverse event data are currently available on the use of anetumab ravtansine in subjects <18 years of age, children are excluded from this study.

ECOG performance status < or equal to 2

Subjects must have adequate bone marrow function as assessed by the following laboratory test results:

  • Hemoglobin greater than or equal to 9.0 g/dL or greater than or equal to 5.6 mmol/L
  • Absolute neutrophil count (ANC) greater than or equal to 1,500/mm3 or greater than or equal to 1.5 x 109/L
  • Platelet count greater than or equal to 100,000/mm3 or greater than or equal to 100 x 109/L

Subjects must have adequate kidney function, with serum creatinine <1.5 x ULN or calculated glomerular filtration rate (GFR) of > 45/mL/min/1.73 m2

Subjects must have adequate liver function as assessed by the following laboratory test results:

  • Total bilirubin less than or equal to 1.5 times the upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 3.0 times ULN in subjects without liver metastases or 5.0 times ULN in subjects with liver metastases

Subjects must have adequate coagulation, as assessed by the following laboratory test results:

  • INR or PT less than or equal to 1.5 x ULN
  • PTT less than or equal to 1.5 x ULN

Due to the lack of adequate reproductive toxicity data on anetumab ravtansine, subjects must use 2 forms of highly effective contraception concomitantly from the initiation of study therapy until 6 months after the last dose of study therapy. Additionally, the use

of condoms is required. It should also be noted that, where 2 forms of effective contraception are required, a subject may choose to use a double-barrier method consisting of condom and cervical occlusive cap / diaphragm with spermicide

Ability of subject to understand and the willingness to sign a written informed consent document.

Subjects must provide a signed informed consent before any screening procedures.

EXCLUSION CRITERIA:

Subjects who have a previous or concurrent cancer that is distinct in primary site or histology from lung adenocarcinoma, except cervical carcinoma in situ, treated basal cell carcinoma, superficial noninvasive bladder tumors or any previous cancer curatively treated <2 years before the start of study treatment.

Subjects who have a history or current evidence of bleeding disorder, i.e. any hemorrhage/bleeding event of CTCAE Grade greater than or equal to 2 within 4 weeks before the start of study treatment.

History of symptomatic metastatic brain or meningeal tumors unless the subject is > 3 months from definitive therapy and has no evidence of tumor growth on an imaging study within 2 weeks prior to study entry. Subjects with brain metastases must not be

undergoing acute corticosteroid therapy or steroid taper. Chronic steroid therapy is acceptable provided that the dose is stable for one month prior to screening.

Subjects who have a history or current evidence of uncontrolled cardiovascular disease including but not limited to the following conditions:

  • Congestive heart failure of New York Heart Association (NYHA) Class III or IV
  • Unstable angina (symptoms of angina at rest) or new-onset angina within <3 months before the start of study treatment.
  • Arterial thrombosis, deep vein thrombosis, or pulmonary embolism within <3 months before the start of study treatment.
  • Myocardial infarction or stroke within <3 months before the start of study treatment.
  • Pericarditis (any CTCAE grade), pericardial effusion (CTCAE Grade greater than or equal to 2) or pleural effusion (CTCAE Grade greater than or equal to 2)
  • Cardiac arrhythmia requiring anti-arrhythmic therapy. Subjects receiving digoxin, calcium channel blockers except verapamil, or beta-adrenergic blockers except propranolol are eligible at the investigator s discretion if the dose has been stable for at least 2 weeks before the start of study treatment. Subjects with sinus arrhythmia and infrequent premature ventricular contractions are eligible at the investigator s discretion.

Subjects who have a left ventricular ejection fraction (LVEF) <50%, as assessed by echocardiogram performed at screening.

Subjects who have a corrected QT (QTcF) interval >480 ms (CTCAE Grade >1) determined by the electrocardiogram (ECG) recorder s algorithm on the screening ECG.

Subjects who have a history or current evidence of uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic blood pressure >95 mmHg at screening despite optimal medical management. Subjects with a history of mild to moderate

hypertension are eligible at the investigator s discretion if the hypertension is adequately controlled by antihypertensive treatment used at a stable dose for at least 2 weeks before the start of study treatment.

Subjects who have a heart rate greater than or equal to 100 beats per minute (bpm) or less than or equal to 45 bpm determined by the ECG recorder s algorithm on the screening ECG.

Women who are pregnant or breast-feeding. Women of reproductive potential must have a negative serum beta human chorionic gonadotropin (beta-HCG) pregnancy test obtained within 7 days before the start of study treatment.

Subjects who have had a major surgery or significant trauma within 4 weeks before the start of study treatment.

Subjects who have had solid organ or bone marrow transplantation.

Subjects who have a history of hypersensitivity to any of the study drugs or their excipients, or a history of severe hypersensitivity to any other antigen.

Subjects who have a history of human immunodeficiency virus (HIV) infection or subjects who have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment due to a theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infection. Subjects with chronic HBV or HCV infection are eligible at the investigator s discretion if the subject is considered non-infectious based on serological markers.

Subjects who have an active clinically serious infection of CTCAE Grade greater than or equal to 2.

Subjects with a non-healing serious wound, ulcer, or bone fracture unrelated to the primary tumor.

Subjects with corneal epitheliopathy or any eye disorder that may predispose the subjects to drug-induced corneal epitheliopathy, or may interfere with diagnosis of treatment-emergent corneal epitheliopathy at the discretion of the investigator in

consultation with the ophthalmologist/optometrist. Low grades of superficial punctate keratitis, within the range seen in the normal population, should not lead to the exclusion of the patient

Subjects experiencing unresolved toxicity of previous antitumor therapy which is CTCAE Grade >1 before the start of study treatment, except for alopecia or hemoglobin greater than or equal to 9.0 g/dL or greater than or equal to 5.6 mmol/L.

Subjects with any clinical condition that is considered unstable or might jeopardize the safety of the subject and/or influence the subject s compliance in the study.

Subjects who have received systemic anticancer therapy within 3 weeks before the start of study treatment. Mitomycin C or nitrosoureas must be excluded within 6 weeks before the start of study treatment.

Subjects who have received radiotherapy to tumor lesions that would be chosen as target lesions (measurable disease) within 4 weeks before the start of treatment, except if there is objective evidence of progression of the lesion by RECIST 1.1 between the

prior radiotherapy and the screening CT or MRI scan. Palliative radiotherapy to nontarget lesions is allowed at the investigator s discretion..

Use of drugs that inhibit renal tubular secretion (e.g. probenecid and cimetidine) within 2 weeks before the start of study treatment.

Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors or strong CYP3A4 inducers within 2 weeks before the start of study treatment.

Subjects who have previously received anetumab ravtansine.

Subjects who are concurrently receiving any other investigational agents.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02839681


Locations
United States, Maryland
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Principal Investigator: Raffit Hassan, M.D. National Cancer Institute (NCI)

Additional Information:
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT02839681     History of Changes
Other Study ID Numbers: 160145
16-C-0145
First Posted: July 21, 2016    Key Record Dates
Last Update Posted: June 14, 2018
Last Verified: June 12, 2018

Studies a U.S. FDA-regulated Device Product: Yes

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):
Lung Adenocarcinoma
Immunotoxin
Immunotherapy

Additional relevant MeSH terms:
Adenocarcinoma
Lung Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Antibodies
Immunoconjugates
Maytansine
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action